This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Bayer AG

Drug Names(s): Sotalol

Description: Sotalol is considered by some to be a beta blocker (and, therefore, a class II antiarrhythmic agent-see below) because its primary action is on the ß-adrenergic receptors (it is not selective for the heart). However, sotalol also has inhibitory action on the outward potassium ion channels of the heart and so is also considered a class III antiarrhythmic agent. Sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity. It also slows atrioventricular (AV) nodal conduction.

The Vaughan Williams Classification is as follows: I (blocks sodium channel; subclasses based on their effect on action potential duration), II (blocks beta-adrenergic receptors), III (blocks potassium efflux), IV (blocks L-type calcium channels, affecting conduction through the AV node between the upper and lower chambers of the heart), V (other).

Deal Structure: In 2006, Bayer acquired Schering AG.

Betapace News

Pink Sheet Berlex Betapace

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug